Significance
DNA damage repair (DDR) is a fundamental aspect of cellular biology that protects against genomic instability and diseases, such as cancer. Numerous proteins are involved, either directly or indirectly, in regulating the DDR process. Valosin-containing protein (VCP), a member of the adenosine triphosphatase family, plays a critical role in the DDR process. Produced in the cytoplasm, VCP must be translocated to the nucleus to participate in DDR. Here, we reveal the molecular mechanism underlying the unclear VCP’s role in the DDR process in a KPNB1-dependent manner and provide an important theoretical basis for developing small-molecule inhibitors targeting this process.
Keywords: DNA damage repair, VCP, KPNB1, nuclear translocation, withaferin A
Abstract
DNA damage repair (DDR) is essential for cancer cell survival and treatment resistance, making it a critical target for tumor therapy. The eukaryotic AAA+ adenosine triphosphatase valosin-containing protein (VCP), which is transported from the cytoplasm into the nucleus, plays a critical role in the DDR process. However, the nuclear translocation and molecular mechanism of VCP for DDR remain elusive. Here, we define VCP as a KPNB1 interacting protein through a combination of chemical and immunoprecipitation mass spectrometry approaches. Further biochemical studies elucidate that KPNB1 directly transports VCP into the nucleus. We also identify withaferin A (WA) as a small molecule that can retard VCP nuclear localization via covalent binding to CYS 158 of KPNB1. Further studies verify WA as an effective antitumor drug candidate via blocking VCP nuclear localization to impact on the DDR pathway in vivo. Our findings underly the unclear VCP’s role in DDR in a KPNB1-dependent manner and provide an important theoretical basis for developing small-molecule inhibitors targeting this process.
DNA serves as a repository of genetic information within cells, with its integrity and fidelity continually threatened by various intrinsic and extrinsic factors. Over the course of long-term evolution, cells have developed complex and interconnected DNA damage repair (DDR) systems, including base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), homologous recombination (HR), and nonhomologous end joining (NHEJ). Each pathway addresses specific types of DNA damage, ensuring comprehensive and coordinated responses to maintain the stability of genetic material (1, 2). Cancer originates from uncontrolled cell proliferation. Distortions in DDR are a hallmark of cancer cells. The balance between DNA damage and repair is disrupted, leading to genomic instability and increased mutation rates. This results in genetic alterations that affect normal cell growth, inactivation of tumor suppressor genes, and ultimately, the survival and proliferation of cancer cells (3). Dysregulation of DDR confers survival advantages to cancer cells and resistance to treatment. Cancer cell survival heavily depends on DDR, providing strategies for cancer therapy. Therefore, DDR pathway proteins as targets for tumor therapy have received widespread attention and research (4, 5). The US Food and Drug Administration (FDA) has approved poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors including olaparib, niraparib, and rucaparib for clinical treatment of ovarian cancer and breast cancer. Thus, thoroughly investigating DDR mechanisms is crucial for enhancing our understanding of tumor biology and driving innovation in tumor treatment strategies.
The ubiquitin-dependent molecular chaperone p97 [referred to as valosin-containing protein (VCP) in vertebrates and CDC48 in worms and lower organisms] is an important eukaryotic AAA+ adenosine triphosphatase involved in DNA double-strand breaks (DSBs) repair within DDR (6). During DDR, VCP forms a complex with the cofactors Ufd1-Npl4 (VCP-Ufd1-Npl4), which identifies and unfolds K48/K63-linked polyubiquitinated proteins, thus facilitating their degradation. This process eliminates proteins released from DSBs to allow the continuation of the DDR process, such as KU70/80, which are essential repair factors that promote NHEJ, while recruiting DNA repair proteins like 53BP1, BRCA1, and RAD51 to promote DSBs repair, thereby preserving cellular genome integrity and stability (7). Reduced activity or level of VCP within the cell impairs both HR and NHEJ pathways, resulting in delayed or even failed DDR (8, 9). Studies have also demonstrated overexpression of VCP could be observed in various malignant tumors, including colon cancer, prostate cancer, hematological malignancies, and melanoma, closely associated with poor prognosis (10, 11). VCP is a nuclear and cytoplasmic protein, it is synthesized in the cytoplasm and therefore has to be translocated to the nucleus. However, the mechanism of nuclear import for VCP remains unknown.
KPNB1 (also known as Karyopherin β1), a member of the Karyopherin β family, serves as a primary nuclear transport receptor responsible for transporting proteins with a molecular weight greater than 40 kDa from the cytoplasm into the cell nucleus (12). Current studies have reported that KPNB1 regulates the nuclear transport of proteins (also known as cargoes), playing an indispensable role in cellular processes such as gene expression regulation, DNA replication, and DDR (13, 14). KPNB1 mediates the nuclear import of crucial DDR proteins such as p53 (15) and DDB2 (16). By facilitating their transport into the nucleus, KPNB1 ensures these proteins can effectively participate in DNA repair processes. Given its role in DDR, KPNB1 represents a potential therapeutic target. Inhibiting KPNB1 could impair the DNA repair capacity of cancer cells, making them more susceptible to DNA-damaging agents such as chemotherapy and radiation. Several studies have highlighted the significance of elevated KPNB1 in various malignancies including prostate cancer, ovarian cancer, and glioblastoma, linking it closely to tumor progression, metastasis, and prognosis (17–19). Consequently, delving deeper into the cargo proteins and related nuclear transport mechanism mediated by KPNB1 may offer insights for advancing tumor treatment strategies.
In this study, we used a tool compound to elucidate a biological pathway that VCP acted as a direct cargo protein of KPNB1. VCP translocation into the nucleus for DDR needed the regulation and interaction with KPNB1. The tool compound, withaferin A (WA) bound to CYS 158 of KPNB1 and disrupted the nuclear translocation of VCP, resulting in induced DNA damage in tumor cells.
Results
WA Targets and Binds to the KPNB1 Protein in Tumor Cells.
Natural compounds play a crucial role in biomedical research due to their enormous scaffold diversity and structural complexity (20). In this study, we aimed to identify potential antitumor candidate drugs or therapeutic target by screening a compound library containing 175 compounds against anaplastic thyroid carcinoma (ATC) (21), one of the most aggressive and rapidly proliferating solid tumors (SI Appendix, Fig. S1A). Among these compounds, WA, a natural bioactive compound derived from Withania somnifera (L.) (22), emerged as the most potent, demonstrating a robust inhibitory effect, with an IC50 about 0.5 μM across the four ATC cell lines (Fig. 1A and SI Appendix, Fig. S1 A–C). To comprehensively elucidate the antitumor mechanism of WA, we utilized a drug affinity responsive target stability (DARTS) assay to identify its target proteins in ATC cells. As the concentration of WA increased, a concentration-dependent band near 100 kDa emerged in both C643 and Ocut-2c cells (Fig. 1B). Following protein molecular weight analysis and repeated mass spectrometry, KPNB1, EEF2, HSP90B1, PFKP, and PYGB were identified as the candidate targets (Fig. 1C and SI Appendix, Fig. S2). Subsequent target validation via DARTS confirmed WA protected KPNB1 protein from proteolysis in both C643 and Ocut-2c cells (Fig. 1D). Further experiments with varying concentrations of WA (0.2, 0.5, and 1 mM) and different protease concentrations (1:1,000 and 1:800) demonstrated that its significant enhancement of KPNB1 stability against protein hydrolases (Fig. 1E and SI Appendix, Fig. S3A). Results from cellular thermal shift assay (CETSA) corroborated the thermostabilization of KPNB1 protein by WA in ATC cells (Fig. 1F and SI Appendix, Fig. S3B). Moreover, similar effects were observed in DARTS and TSA assays with purified KPNB1 protein (Fig. 1 G and H and SI Appendix, Fig. S3 C and D). Finally, microscale thermophoresis (MST) analysis (Fig. 1I, KD = 13.9 nM) and the reduced WA sensitivity observed in KPNB1 knockdown ATC cells (SI Appendix, Fig. S3E) further provided compelling evidence of KPNB1 as a direct target of WA.
Fig. 1.
WA inhibits ATC cells through binding to KPNB1 protein. (A) The molecular structure of WA and the IC50 of WA against four ATC cell lines. (B) DARTS assay was conducted to identify potential target of WA in C643 and Ocut-2c cells. (C and D) Targets validation by DARTS. (E and F) DARTS (E) and CETSA (F) were used to evaluate the binding between WA and KPNB1 protein in C643 and Ocut-2c cells. (G and H) DARTS (G) and TSA (H) were used to evaluate the binding between WA and purified KPNB1 protein. (I) Binding affinity of WA and purified KPNB1 protein was analyzed by MST assay.
WA Covalently Binds to CYS 158 of KPNB1.
Subsequently, we explored the binding site of WA on KPNB1. The irreversibility effect of WA on ATC cell inhibition suggested a potential covalent binding of WA to KPNB1 (SI Appendix, Fig. S4A). Moreover, the dose-dependent rescue of ATC cell growth inhibition by competitive binding agents for cysteine residues, such as N-acetylcysteine (NAC) and dithiothreitol (DTT) (SI Appendix, Fig. S4B), provided further evidence supporting the hypothesis that WA might covalently bind to cysteine residues of KPNB1.
To delve deeper into the possible binding motif of WA on KPNB1, the protein, comprising 19 HEAT repeat sequences (23), was divided into two fragments: KPNB1 (1-499aa) (HEAT 1-11) and KPNB1 (500-876aa) (HEAT 12-19) (Fig. 2A). DARTS analysis revealed that WA conferred protection effect against protease to the 1-499aa peptide fragment of KPNB1 but not the 500-876aa fragment (Fig. 2B and SI Appendix, Fig. S4C). Truncating the 1-499aa peptide to a shorter fragment [1-313aa (HEAT 1-7)] found that WA significantly stabilized this fragment against protease hydrolysis (Fig. 2C and SI Appendix, Fig. S4D), indicating the binding site might be located in 1-313aa of KPNB1. Subsequent mass spectrum analysis identified CYS 158 and CYS 228 as possible covalent binding sites in purified KPNB1 (1-313aa) protein (Fig. 2D). For further verification, we purified the 127-253aa peptide fragment of KPNB1, and the positive DARTS results further supported CYS 158 and/or CYS 228 as potential binding sites of WA on KPNB1 (Fig. 2E and SI Appendix, Fig. S4E). CCK-8 results demonstrated that the KPNB1C158A mutation significantly diminished WA’s antitumor activity in ATC cells, while the KPNB1C228A mutation had a minimal impact (Fig. 2F). Additionally, DARTS confirmed that WA lost its protective effect on the KPNB1C158A protein but not on the KPNB1C228A (Fig. 2G and SI Appendix, Fig. S4F). The results of the MST assay demonstrated that WA showed no binding to the KPNB1C158A protein at low concentrations but a significantly weaker binding at high concentrations of WA, with a KD value of 90.41 µM (Fig. 2H and SI Appendix, Fig. S4G), suggesting the mutation at CYS 158 markedly reduced the binding capability of WA to KPNB1. These findings collectively indicated that WA covalently bound to CYS 158 of KPNB1.
Fig. 2.
WA covalently binds to CYS 158 of KPNB1. (A) KPNB1 and KPNB1 fragments in this research. (B and C) DARTS assay detected the protease protection of WA on purified peptide segments of KPNB1 protein [1-499aa and 500-876aa (B), 1-313aa (C)]. (D) WA binds to CYS 158 and CYS 228 of KPNB1 suggested by mass spectrometry. (E) DARTS assay detected the protease protection of WA on purified peptide segments of KPNB1 protein (127-253aa). (F) KPNB1C158A mutation significantly diminished WA’s antitumor activity in ATC cells. KPNB1WT, KPNB1C158A, and KPNB1C228A plasmid were transfected in the KPNB1-knockdown C643 and Ocut-2c cells, respectively. Inhibitory rates of C643 and Ocut-2c cells treated with different concentrations of WA for 48 h. (G) DARTS analyses of the purified C158A and C228A mutant KPNB1 protein. (H) Binding affinity of KPNB1C158A and WA was analyzed by MST assay. (I) Docking predicted binding sites between WA and KPNB1. The data were expressed as the mean ± SEM for at least triplicate experiments. ns, no significance; *P < 0.05; **P < 0.01; ***P < 0.001.
The α,β-unsaturated ketone presented in WA is likely the binding moiety, given its electrophilic nature (24). Cell proliferation experiments revealed a significant decrease in the inhibitory effects on ATC cells for dihydrowithaferin A (2H-WA) compared to WA (SI Appendix, Fig. S4H), indicating that the α,β-unsaturated ketone of WA served as the functional group responsible for its activity. The molecular docking analysis revealed that the α,β-unsaturated ketone of WA (C-3) formed a covalent bond with CYS 158 in KPNB1. Additionally, the hydroxyl groups at C-4 and C-27 formed hydrogen bonds with GLU 203 and LYS 68, respectively (Fig. 2I).
VCP Is a KPNB1 Interacting Protein, and KPNB1 Directly Transports VCP into the Nucleus.
We then investigated the effect of WA on KPNB1 levels and distribution in ATC cells, finding no significant changes in either aspect (SI Appendix, Fig. S5 A and B). Since KPNB1 plays a crucial role as a nuclear transport protein (18), we speculated that WA might influence its function. Therefore, we conducted coimmunoprecipitation (co-IP) analysis to explore the possible cargo proteins of KPNB1 in ATC. The co-IP results revealed distinct bands at 70 to 100 kDa and 100 to 150 kDa in the control group compared to the WA-treated group in two ATC cell lines (Fig. 3A), suggesting that WA inhibited the binding of certain proteins to KPNB1. Mass spectrometry analysis identified VCP (around 100 kDa) and hnRNPU, DDX1, RANGAP1 (at 100 to 150 kDa) with higher scores in these bands (SI Appendix, Table S1). Western blot showed nonspecific binding of hnRNPU, DDX1, and RANGAP1 proteins while KPNB1 could pull down VCP protein from ATC cells (Fig. 3B), and vice versa (Fig. 3C). Furthermore, WA reduced the level of VCP protein pulled down by KPNB1 in ATC cells (Fig. 3D). Western blot and immunofluorescence analysis confirmed a decrease in the nuclear localization of VCP following WA treatment (Fig. 3 E and F). These findings suggested that VCP might serve as a cargo protein of KPNB1, and WA disrupted KPNB1-mediated translocation of VCP protein into the nucleus. To corroborate this observation, we employed KPNB1 inhibitors [importazole (IPZ) and INI-43], known to inhibit nuclear transport of cargo proteins by binding to KPNB1. Our findings demonstrated a significant reduction in nuclear VCP levels alongside increased cytoplasmic expression (Fig. 3G). Knocking down KPNB1 also resulted in a reduced level of VCP protein in the nucleus in ATC cells (Fig. 3 H and I). Further validation across various tumor cells underscored the necessity of KPNB1-mediated nuclear transport for VCP entry (Fig. 3J). Biolayer interferometry (BLI) revealed a KD value of 7.50 nM between KPNB1 and VCP (Fig. 3K), supporting their direct binding.
Fig. 3.
VCP is a cargo protein of KPNB1. (A) Co-IP analysis to identify cargo proteins affected by WA-mediated nuclear transport inhibition. C643 and Ocut-2c cells were treated with DMSO or WA for 24 h. KPNB1-associated proteins were immunoprecipitated using KPNB1 antibodies and analyzed by SDS-PAGE with Coomassie blue staining. Distinct bands at ~100 kDa and ~130 kDa were observed in both groups but were less intense in the WA-treated group, suggesting reduced binding to KPNB1. (B) Co-IP assay was used to detect the binding between KPNB1 and VCP/hnRNPU/DDXI/RANGAP1. (C) Co-IP assay with VCP antibody indicated an interaction between VCP and KPNB1. (D) Co-IP assay with KPNB1 antibody showed that KPNB1 could bind to VCP. WA preincubation for 24 h attenuated the binding of KPNB1 and VCP in C643 and Ocut-2c cells. (E and F) The levels of VCP protein in total protein, cytoplasm, and nucleus in C643 and Ocut-2c cells were detected by immunoblotting (E) and confocal microscopy analysis (F). (G) Confocal microscopy analysis of KPNB1 protein (green) and VCP protein (red) in C643 and Ocut-2c cells treated with 20 μM IPZ or 5 μM INI-43 for 24 h. (Scale bar, 10 μm.) (H and I) The levels of VCP in total protein, cytoplasm, and nucleus in C643 and Ocut-2c cells were detected by immunoblotting (H) and confocal microscopy analysis (I, scale bar, 10 μm). (J) Confocal microscopy analysis of VCP protein (green) in Hela, HCT116, and A549 cells treated with IPZ for 24 h. (Scale bar, 10 μm.) (K) Interaction between purified full KPNB1 and VCP protein was analyzed by the BLI assay.
Then, we conducted rigid protein–protein docking between KPNB1 and VCP, revealing hydrogen bonds and salt bridges formed between specific amino acid residues of the 426 to 753 peptide segment of VCP and KPNB1, such as THR 254-ASP 450, ALA 480-ASP 671, LYS 62-GLN 714, and LYS 73-GLN 714, among others (Fig. 4A and SI Appendix, Fig. S6 A and B). Each HEAT repeat of KPNB1 typically consists of two helices (A and B) connected by loops. The A helix is situated on the protein’s outer surface, forming a convex structure, while the B helix is located on the inner side, forming a concave shape (23). The docking results showed that most amino acids of VCP bound to the B helix of KPNB1 (SI Appendix, Fig. S6C), suggesting VCP inserted into the concave pocket of KPNB1. Notably, we identified that the 691 to 717 peptide segment of VCP (red in Fig. 4B) was inserted directly into 2-5 HEAT repeat of KPNB1 protein (61-74aa, 155-162aa, and 200aa, yellow in Fig. 4B), which formed a “card slot” to secure VCP on KPNB1, suggesting that 691 to 717 peptide segment of VCP, along with the 2-5 HEAT repeat sequences of KPNB1, constituted the grip region between KPNB1 and VCP. BLI analysis showed that a truncated VCP (1-690aa) lacked concentration-dependent binding to KPNB1, and no KD value could be determined (Fig. 4C). Additionally, cells transfected with the VCP (1-690aa) plasmid showed cytoplasmic retention, while full-length VCP predominantly localized to the nucleus (Fig. 4D), indicating that the 691-717aa region was essential for KPNB1-mediated nuclear transport of VCP. Furthermore, VCP mutants (E710A, R713A, Q714A, T715A, and P717A) exhibited significantly reduced binding affinity to KPNB1 (KD values of 348 nM for the VCP mutants vs. 7.50 nM for VCP, Fig. 4E), highlighting the importance of these residues in VCP’s interaction with KPNB1. The results of BLI analysis showing a strong binding affinity (KD value of 6.43 nM) between VCP and the 33-211aa of KPNB1 (HEAT 2-5) also supported that the 2-5 HEAT repeats of KPNB1 were critical for the interaction of VCP and KPNB1 (Fig. 4F). Notably, WA and VCP were found to share the same binding pocket on KPNB1 (SI Appendix, Fig. S6D). The binding model of the WA–KPNB1–VCP ternary complex confirmed that WA binding caused an outward rotation of KPNB1, occupying the VCP-binding site and introducing steric hindrance that competitively inhibited their interaction (Fig. 4G). BLI results further confirmed that WA dose dependently disrupted VCP-KPNB1 (33-221aa) binding (Fig. 4H), with the KPNB1C158A mutant reducing VCP binding affinity (KD value of KPNB1C158A 50 nM vs. 7.5 nM of KPNB1, Fig. 4I).
Fig. 4.
The binding sites between VCP and KPNB1. (A and B) Surface diagram of the docking model (A) and their interfacing residues (B) between KPNB1 and VCP protein (KPNB1, blue; VCP, green). (C) Binding affinity of purified KPNB1 and 1-690aa segments of VCP protein was analyzed by BLI assay. (D) The level of 1-690aa segments of VCP protein in ATC cells was detected by confocal microscopy analysis. (Scale bar, 10 μm.) (E) Binding affinity of purified KPNB1 and mutated VCP protein (E710A, R713A, Q714A, T715A, P717A) was analyzed by BLI assay. (F) Binding affinity of purified 33-211aa segments of KPNB1 and VCP protein was analyzed by BLI assay. (G) Computational docking of WA (red), occupying the same binding sites of KPNB1 (cyan) and VCP (green). (H) Competitive binding of WA to 33-211aa segments of KPNB1 disrupting 33-211aa segments of KPNB1–VCP interaction was analyzed by BLI assay. (I) Binding affinity of purified KPNB1C158A and VCP protein was analyzed by BLI assay.
Therefore, our findings confirmed that KPNB1 interacted with and transported VCP into the nucleus via the critical 691-717aa region of VCP and the 2-5 HEAT repeats of KPNB1. WA competed VCP for the same binding pocket on KPNB1, effectively inhibiting their interaction.
WA Induces DNA Damage to Trigger G2/M Arrest and Apoptosis via Blocking VCP Nuclear Localization.
Impaired nuclear entry of VCP may disrupt cellular DDR, leading to DNA damage (9, 10). The results that WA and IPZ which disrupted KPNB1 nuclear transport of VCP protein increased the levels of γ-H2AX protein (a marker of DNA damage) in different tumor cells (Fig. 5A and SI Appendix, Fig. S7A) further supported the role of VCP protein in DDR. Alkaline comet assay results corroborated significant DNA damage was induced by WA in ATC cells (Fig. 5B). During the DDR processes, VCP “pushes” the proteins at DSBs (such as KU70/80) away from the DNA break sites through the recognition of ubiquitinated proteins and promotion of their degradation. Simultaneously, VCP “pulls” DDR proteins like 53BP1, BRCA1/2, and RAD51 to promote DDR pathways, such as NHEJ and HR (25) (SI Appendix, Fig. S7B). The flow cytometry analysis of cells transfected with pDR GFP and pLCN DSB Repair Reporter (DRR) plasmids indicated that WA affected the efficiency of HR and NHEJ in ATC cells (Fig. 5C). Western blot analysis revealed an increase in the levels of K48 and K63 ubiquitin in the nucleus of WA-treated ATC cells (Fig. 5D and SI Appendix, Fig. S7C), but minimal impact on the levels of KU70 and KU80 proteins on chromatin (SI Appendix, Fig. S7D). The co-IP results showed that ubiquitination levels of KU80 were increased in WA-treatment cells (Fig. 5E). These results indicated the polyubiquitinated DDR proteins at DNA break sites were not recognized and degraded by VCP due to WA blocking its nuclear localization. On the other hand, the results that WA reduced the levels of DNA repair proteins such as BRCA1, DNA-PKcs, 53BP1, and RAD51 on chromatin (SI Appendix, Fig. S7E) and prevented 53BP1 and RAD51 from colocalizing with γ-H2AX (Fig. 5F) in two ATC cells were consistent with previous experimental results, suggesting that the inability to recruit DNA repair proteins to the DNA break sites is due to the absence of VCP in WA-treated cells. Next, we performed VCP knockdown using sh-RNA and observed no additive effect of VCP loss combined with WA treatment on γ-H2AX levels (Fig. 5G). To explore the role of VCP nuclear localization, we overexpressed VCP with a nuclear localization sequence (NLS-VCP) or those lacking an NLS. NLS-VCP overexpression reduced WA-induced γ-H2AX level, whereas VCP without an NLS had no significant effect (Fig. 5H). Immunofluorescence further supported these results (Fig. 5I and SI Appendix, Fig. S7F). In NLS-VCP plasmid transfected cells, WA did not increase γ-H2AX level (yellow arrows in Fig. 5I), while WA significantly increased γ-H2AX in unsuccessfully transfected cells (red arrows in Fig. 5I). Cells overexpressed VCP lacking an NLS showed reduced nuclear VCP localization and increased γ-H2AX after WA treatment (white arrows in Fig. 5I). Similarly, alkaline comet assay revealed that NLS-VCP overexpression attenuated WA-induced DNA damage, while VCP without an NLS failed to rescue DNA damage (Fig. 5J). These results supported that WA bound with KPNB1 to hinder VCP translocate into the nucleus for DDR, thereby resulting in DNA damage in ATC cells.
Fig. 5.
Molecular mechanism of WA-induced DNA damage via blocking the nuclear translocation of VCP. (A) The level of γ-H2AX protein in C643 and Ocut-2c cells treated with WA for 24 h. (B) WA induced DNA damage in ATC cells. Alkaline comet assays of C643 and Ocut-2c cells treated with 0.5 μM WA for 24 h to measure both single- and double-strand DNA breaks. The DNA in tails was quantified to indicate the degree of DNA damage. (C) WA impaired HR repair and NHEJ repair. HR reporter and NHEJ reporter were used to detect the effect of WA on HR and NHEJ repair efficiency in U2OS cells. (D) The levels of K48 and K63-ubiquitinated proteins in the nucleus of C643 and Ocut-2c cells treated with WA for 24 h. (E) Co-IP assay using a KU80 antibody showed the level of ubiquitin-conjugated to KU80 protein increased in C643 and Ocut-2c cells following 24 h treatment with WA. (F) WA prevented 53BP1 and RAD51 from colocalizing with γ-H2AX in ATC cells. C643 and Ocut-2c cells were pretreated with or without WA for 24 h followed by irradiation (8 Gary). Confocal microscopy analysis of 53BP1 protein (green) or RAD51 protein (green) and γ-H2AX protein (red) was conducted. (Scale bar, 10 μm.) (G) The level of γ-H2AX protein in C643 and Ocut-2c cells was examined under conditions of VCP knockdown (sh-VCP-1) and subsequent treatment with WA for 24 h. (H) The level of γ-H2AX protein in C643 and Ocut-2c cells overexpressing NLS-VCP-flag or VCP-flag treated with WA for 24 h. (I) Confocal microscopy analysis of NLS-VCP-GFP protein (green) or VCP-GFP protein (green) and γ-H2AX protein (red) was conducted (scale bar, 10 μm; the corresponding single-channel images are presented in SI Appendix, Fig. S7F). C643 and Ocut-2c cells overexpressing NLS-VCP-GFP or VCP-GFP were treated with WA for 24 h. Red arrows indicated cells that did not successfully overexpress the NLS-VCP-GFP or VCP-GFP plasmid; yellow arrows indicated cells that successfully overexpressed NLS-VCP-GFP; white arrows indicated cells that successfully overexpressed VCP-GFP. (J) Alkaline comet assays were conducted on C643 and Ocut-2c cells under conditions of VCP knockdown (sh-VCP-1) or overexpression of NLS-VCP-GFP or VCP-GFP, followed by treatment with WA for 24 h, to measure both single- and double-strand DNA breaks. The DNA in the tails was quantified to indicate the degree of DNA damage. The data were expressed as the mean ± SEM for at least triplicate experiments. ns, no significance; ***P < 0.001.
Upon cellular DNA damage, DDR mechanisms initiate cell cycle arrest, facilitating DNA repair. In cases where the damage is irreparable, cells trigger apoptosis (26). Flow cytometry analysis revealed that WA markedly induced G2/M arrest after 24 h of treatment and apoptosis after 48 h in ATC cells (Fig. 6 A and B and SI Appendix, Fig. S8 A and B). Next, we used Ocut-2c and MKH28 cells, which exhibited relatively low KPNB1 levels (SI Appendix, Fig. S8 C and D), and transfected them with wild-type KPNB1 (KPNB1WT) plasmid or KPNB1C158A mutant plasmid to investigate whether CYS 158 was the critical binding site for WA. CCK-8 assay showed that KPNB1WT overexpression reduced sensitivity to WA, whereas KPNB1C158A did not reveal a significant effect (SI Appendix, Fig. S8E). Flow cytometry further confirmed that KPNB1WT partially rescued WA-induced G2/M arrest and apoptosis, while KPNB1C158A did not (Fig. 6 C and D and SI Appendix, Fig. S8 F and G). Additionally, overexpression NLS-VCP rescued WA-induced G2/M arrest and apoptosis, but VCP lacking the NLS had no impact on the cellular effects of WA (SI Appendix, Fig. S8 H and I). These results confirmed that WA bound to KPNB1 at CYS 158, disrupting its interaction with VCP and inhibiting VCP nuclear translocation.
Fig. 6.
The molecular mechanism of WA-inducing G2/M arrest and apoptosis in ATC cells. (A and B) WA induces G2/M arrest (A) and apoptosis (B) in ATC cells. C-D, Overexpression of KPNB1WT rescued WA-induced G2/M arrest (C) and apoptosis (D) in ATC cells. (E and F) The levels of cell cycle checkpoint proteins (E) and ATM/ATR pathway proteins (F) in C643 and Ocut-2c cells treated with WA for 24 h. (G) Caspase-3 and 9 activities of C643 and Ocut-2c cells treated with WA for 48 h. (H and I) Western blot analyses of cleaved caspase 3 and 9 (H), Mcl-1, Bcl-2, and Bax (I) protein levels in C643 and Ocut-2c cells treated with different concentrations of WA for 48 h. (J) Flow cytometric analysis of mitochondrial membrane potential evaluated by JC-1 assay in C643 and Ocut-2c cells treated with WA for 48 h. (K) Flow cytometric analysis of ROS staining evaluated by the fluorescent dye DCFH-DA assay in C643 and Ocut-2c cells treated with WA for 48 h. (L and M) The level of cytochrome C (Cyto C) protein in total protein, cytoplasm, and mitochondria in ATC cells was detected by immunoblotting (L) and confocal microscopy analysis (M, scale bar, 10 μm). C643 and Ocut-2c cells treated with WA for 48 h. The data were expressed as the mean ± SEM for at least triplicate experiments. ns, no significance; **P < 0.01; ***P < 0.001.
Then, we investigated the molecular mechanism of WA-inducing G2/M arrest and apoptosis in ATC cells. Our further findings demonstrated that WA activated the ATR/Chk1 and ATM/Chk2 pathways in response to DNA damage, thereby inhibiting Cdc25C and preventing the dephosphorylation of Cdk1 at THR 14 and TYR 15, consequently leading to G2/M arrest in ATC cells (Fig. 6 E and F). Interestingly, the ATM inhibitor KU-55933 significantly mitigated the inhibitory effect of WA on ATC cells, while the ATR inhibitor VE-821 exhibited minimal impact (SI Appendix, Fig. S9), suggesting that the activation of ATM might primarily mediate WA-induced G2/M arrest in ATC cells. Furthermore, DNA damage commonly triggers the mitochondrial apoptosis pathway (27). Our investigation revealed that WA reduced the levels of antiapoptotic proteins Bcl-2 and Mcl-1, leading to a marked decrease in mitochondrial membrane potential and increased ROS production in ATC cells. Additionally, WA facilitated the release of Cytochrome C from mitochondria into the cytoplasm, activating caspase 9 and caspase 3 and ultimately inducing apoptosis in ATC cells (Fig. 6 G–M).
WA Is a Promising Lead Compound against ATC In Vivo.
Subsequently, ATC xenograft tumor models were established to examine the inhibitory effect of WA on ATC tumors in vivo (Fig. 7A). In the C643 (Key driver mutation: HRASG13R) xenograft model, WA dose dependently inhibited ATC tumor growth at doses of 10 and 15 mg/kg, with inhibitory rates of 55.25% and 72.63%, respectively (Fig. 7 B and C and SI Appendix, Fig. S10A, P < 0.001). In the Ocut-2c (Key driver mutation: BRAFV600E) xenograft model, 15 mg/kg of WA significantly inhibited tumor growth, with an inhibitory rate of 79.48% (Fig. 7 D and E and SI Appendix, Fig. S10A, P < 0.001). The inhibitory effect of WA in the Ocut-2c xenograft model was comparable to that of the positive drug D + T (dabrafenib in combination with trametinib). Immunohistochemical analysis of tumor tissues revealed a significant reduction in Ki67 staining in ATC tumor tissues following WA treatment compared to the control group (Fig. 7F), and TdT-mediated dUTP nick end labeling (TUNEL) analysis demonstrated that WA induced substantial apoptosis in ATC tumor tissues (Fig. 7G), indicating that WA inhibited tumor cell proliferation in vivo.
Fig. 7.
WA suppresses tumor growth in vivo. (A) The scheme of the animal experiments. (B and C) WA exerted an inhibitory effect on the tumor growth of C643-derived tumor xenografts (n = 5). Mice were intraperitoneal (i.p.) administered WA (10 mg/kg, 15 mg/kg) or vehicle every 2 d. (B) Tumor volume curves. (C) Tumor weight. (D and E) WA exerted an inhibitory effect on the tumor growth of Ocut-2c-derived tumor xenografts (n = 5). Mice were i.p. administered WA (15 mg/kg) or vehicle, or orally administered 30 mg/kg D + 0.6 mg/kg T every 2 d. (D) Tumor volume curves. (E) Tumor weight. (F) The hematoxylin–eosin (H&E) staining and immunohistochemistry staining analysis of Ki67 level in ATC tumor tissues. (Scale bar, 100 μm.) (G) Tumor cell apoptosis analyzed by TUNEL assay in the control and WA-treated tumor tissues. (Scale bar, 100 μm.) (H and I) WA inhibited the formation and growth of ATC tumor organoids (n = 6). (H) The scheme of ATC tumor organoids culture and WA treatment. (I) Effect of 1 μM WA on ATC organoids. The data were expressed as the mean ± SEM for at least triplicate experiments. ns, no significance; *P < 0.05; **P < 0.01; ***P < 0.001.
Additionally, a patient-derived ATC tumor organoid also revealed that WA significantly impeded the formation and growth of tumor organoids (Fig. 7 H and I, P < 0.001), indicating that WA was a promising lead compound for ATC treatment.
Preliminary investigations into toxic effects demonstrated that treatment with WA at doses of 10 and 15 mg/kg had minimal impact on mouse body weight compared to the control group (SI Appendix, Fig. S10B) and did not cause significant organ damage in mice (SI Appendix, Fig. S10C). Thyroid function testing indicated normal thyroid function in WA-treated mice (SI Appendix, Fig. S10D). These results indicated that WA had a high safety profile for in vivo use.
KPNB1/VCP Is a Potential Target for Cancer Treatment.
Consistent with our findings in vitro, immunohistochemical staining results revealed that WA did not affect the level of KPNB1 protein but decreased the level of VCP protein in tumor cells (SI Appendix, Fig. S11A). Subsequently, we explored the clinical relevance of KPNB1 and VCP in tumors to assess their potential as therapeutic targets in ATC. Analysis of data from the Gene Expression Omnibus (GEO) database revealed high expression of KPNB1 and VCP in ATC and PTC compared to normal tissues (SI Appendix, Fig. S11B). Clinical samples further confirmed strong positive expression levels of KPNB1 and VCP proteins in PTC and ATC tumors (SI Appendix, Fig. S11C). Survival probability analysis demonstrated that thyroid cancer patients with high expression of KPNB1 and VCP had poorer prognosis (SI Appendix, Fig. S11D). Furthermore, both KPNB1 inhibitors (IPZ and INI-43) and VCP inhibitors (NMS-873 and CB-5083) dose dependently inhibited ATC cell proliferation (SI Appendix, Fig. S11E). KPNB1 or VCP knockdown in ATC cells significantly inhibited proliferation and colony formation (SI Appendix, Fig. S12), suggesting that targeting KPNB1 and VCP could be a potential treatment approach for ATC. Further analysis across multiple tumor types revealed high expression of KPNB1/VCP, associated with adverse prognoses (SI Appendix, Fig. S13). Evaluation of WA, KPNB1 inhibitors (IPZ and INI-43), and VCP inhibitors (NMS-873 and CB-5083) on KPNB1/VCP highly expressed tumor cells revealed significant inhibition of proliferation across various cancer cell lines (SI Appendix, Fig. S14), suggesting that KPNB1 and VCP might serve as potential therapeutic targets in cancer treatment with significant clinical implications.
Additionally, a positive correlation was observed between KPNB1 and NHEJ or HR repair proteins not only in thyroid cancer (SI Appendix, Fig. S15A) but also across all pan-cancers (SI Appendix, Fig. S15B). This highlighted the crucial role of KPNB1 as a nuclear transport factor in DDR across diverse cancers, providing insights for the development of targeted antitumor therapies focused on DDR.
Discussion
In this study, we demonstrated that WA, a natural bioactive compound derived from the medicinal plant Withania somnifera (L.), was a promising lead compound for ATC treatment. Mechanically, WA acted as a KPNB1 inhibitor through covalently binding to CYS 158 of KPNB1, thereby disrupting its nuclear transport function. During this process, we elucidated that VCP was a direct cargo protein of KPNB1. VCP translocation into the nucleus for DDR required nuclear translocation and interaction with KPNB1.
Prompted by the discovery of exportin-1 drug selinexor, importins are emerging as promising targets in cancer therapy (13, 28, 29). Various importins, including KPNB1, importin-α2, and importin-α4, have been implicated in the progression of numerous tumors (30–32). However, the therapeutic potential of importins is hampered by the lack of inhibitors, hindering further clinical investigation. Bioactive natural products serve as primary resources for new drug development and crucial molecular tools in biomedical research (21, 33). WA is a natural compound containing potential electrophilic sites for cysteine thiol additions. Several studies have reported its various biological activities through its covalent binding with target proteins (24, 34, 35). Our investigation, through DARTS, mass spectrum, and site mutation analysis, demonstrates that the anti-ATC effect of WA attributed to its covalent binding to CYS 158 of KPNB1. Considering the hydroxyl group in A ring at the allylic position facilitates cysteine addition while the epoxide attack is hindered due to the conformation of the AB-ring (36), we demonstrated α,β-unsaturated ketone in A-ring was the main moiety binding with CYS 158 of KPNB1, further supporting the significance of α,β-unsaturated ketone for binding. Compared to other KPNB1 inhibitors like IPZ and INI-43, which broadly disrupt nuclear transport by targeting RanGTP interactions or overlapping Ran- and KPNA2-binding regions (331-361aa) (37, 38), our study offers insights. Our research not only pinpoints the specific binding site of WA on KPNB1 (CYS 158) but also elucidates its mechanism of action, which involves inhibition of KPNB1-mediated nuclear transport of VCP. By defining the key interaction domains between KPNB1 and VCP and demonstrating that WA competes with VCP for KPNB1 binding without affecting KPNB1’s nuclear localization, our findings highlight WA’s specificity and offer a strong foundation for the development of more effective and highly specific KPNB1-targeted therapeutics.
As a primary nuclear transport receptor, KPNB1 regulates protein nuclear import through two primary pathways. In the classical import pathway, cargo proteins are identified by importin-α via an NLS, forming a dimer complex that binds with KPNB1 for nuclear transport as a trimeric complex. Alternatively, in the nonclassical pathway, KPNB1 directly binds cargo proteins (39, 40). Proteins like PTHrP, Smad-3, SREBP-2, and GAL4 have been shown to directly interact with KPNB1 for nuclear transport (41). Our study demonstrates that KPNB1 mediates the nuclear import of VCP in a nonclassical pathway. Pharmacological inhibition of KPNB1 or its knockdown significantly reduced nuclear VCP levels. Co-IP and BLI assays further confirmed a direct interaction between VCP and KPNB1, identifying VCP serves as a direct cargo protein in KPNB1-mediated nuclear transport.
VCP is a crucial protein for maintaining cellular protein homeostasis (42). Most current VCP inhibitors, such as NMS-873 and CB-5083, directly target VCP to disrupt its diverse cellular functions, including proteostasis and DDR (43, 44). However, their broad mechanism of action often results in significant off-target effects and toxicity, and resistance due to mutations, limiting their therapeutic potential (45, 46). Our study, in contrast, offers a targeted strategy by selectively disrupting VCP’s nuclear localization but not affecting its activity. WA selectively inhibits VCP’s nuclear localization through elucidating the interaction between KPNB1 and VCP without interfering with its cytoplasmic functions. This mechanism minimizes potential side effects associated with pan-VCP inhibition, offering a more precise strategy for targeting VCP’s role in DNA damage repair. WA retaining VCP’s activity while exhibiting cytostatic effect also aligns with previous findings (47). Our results reveal that nuclear VCP is critical for DNA repair, interacting with chromatin-associated proteins to resolve DNA lesions. Blocking VCP’s nuclear transport with WA disrupts this process, leading to increased γ-H2AX levels and impaired cell survival. Importantly, this disruption does not compromise VCP’s cytoplasmic proteostasis roles, underscoring the specificity of nuclear-localized VCP in maintaining genomic stability.
Recent research has advanced understanding of VCP nuclear translocation and its regulatory proteins. Korner et al. found that VCF1/2 interacts with VCP’s N-domain via a conserved C-terminal helix, enabling a “piggy-back” nuclear import mechanism through intrinsic nuclear localization signals, enhancing VCP’s chromatin association (48). Another study showed that p37 fine-tunes VCP’s nucleocytoplasmic distribution by competing with factors influencing cytosolic retention or nuclear entry, though it does not mediate direct nuclear transport. Disease-related VCP mutations increase p37 binding, reducing nuclear localization and impairing DNA repair (49). However, these mechanisms regulating VCP nuclear transport differ significantly with KPNB1 in their roles and mechanisms. Our study confirms that KPNB1 interacts with VCP to mediate its nuclear translocation for DNA damage. The binding sites of VCP to KPNB1 are mainly located at the N terminus of KPNB1 (2-11 HEAT repeats) and 691 to 717 peptide segment of VCP inserting into 2-5 HEAT repeats of KPNB1 serve as the grip region for VCP binding to KPNB1.
Furthermore, our research findings confirm that WA disrupts the KPNB1–VCP interaction, consequently blocking VCP nuclear transport. This disruption occurs because WA binds to specific sites on KPNB1 (LYS 68, CYS 158, and GLU 203), which causes KPNB1 to rotate outward and occupies the VCP site within its original binding pocket. Since the binding of WA to KPNB1 is covalent and irreversible, once WA enters the cell and binds to the KPNB1 protein, it creates substantial steric hindrance and results in competitive inhibition, thereby impeding the role of KPNB1 in VCP nuclear transport required for DDR. The BLI assays showing reduced VCP binding to KPNB1C158A and WAs competing with VCP for KPNB1 highlight the significance of WA’s binding sites in this interaction.
In sum, we elucidate the nuclear journey of VCP protein and demonstrate that interacting with KPNB1 is the necessary condition for VCP’s nucleus translocation. As a cargo protein, KPNB1 interacts with VCP and mediates its nuclear translocation. The peptide segment 691 to 717 peptide segment of VCP and the 2-5 HEAT repeat sequences of KPNB1 appear to constitute the critical binding region between VCP and KPNB1. VCP identifies ubiquitinated proteins at DSBs, such as KU70/80, to promote their degradation, and recruits DNA repair proteins like 53BP1 and RAD51 to enhance DDR. However, if KPNB1’s nuclear transport function is suppressed, the nuclear translocation of VCP is inhibited. For instance, the small-molecule compound WA binds to KPNB1, disrupting its interaction with VCP, thereby impeding VCP’s nuclear translocation and inducing DNA damage in cells (Fig. 8). Moreover, the clinical relevance of KPNB1/VCP in tumors proposes that inhibiting KPNB1/VCP could be a viable treatment approach. These findings have significant implications for clinical tumor interventions.
Fig. 8.
Schematic of the molecular mechanism by which KPNB1 transports VCP into the nucleus for DDR. In response to DDR, KPNB1 interacts with VCP and mediates its nuclear translocation. Once inside the nucleus, VCP identifies ubiquitinated proteins from DSBs, such as KU70/80, to promote their degradation, and recruits DNA repair proteins like 53BP1 and RAD51 to enhance DDR. However, if KPNB1’s nuclear transport function is suppressed, the nuclear translocation of VCP is inhibited. For instance, the small-molecule compound WA binds to KPNB1, disrupting its interaction with VCP, thereby impeding VCP’s nuclear translocation and inducing DNA damage in cells.
Materials and Methods
All animal studies were approved by the Institutional Animal Care and Use Committee of Sichuan University, while the ATC organoid culture procedures were specifically approved by the Biomedical Research Ethics Committee of West China Hospital, Sichuan University. Our experimental approach incorporated three major methodological categories: 1) target identification through DARTS, CETSA, MST, and molecular docking; 2) protein interaction analysis using co-IP, BLI, site-directed mutagenesis, and immunofluorescence staining; and 3) mechanistic investigations employing western blot, flow cytometry, comet assays, HR and NHEJ reporter assays, confocal microscopy, plasmid transfection, and others. Complete methodological details and additional technical specifications are available in SI Appendix, Materials and Methods. All error bars indicate the SEM, and statistical significance was assessed using a t test, as detailed in the corresponding figure legends.
Supplementary Material
Appendix 01 (PDF)
Acknowledgments
We thank Rui Zhang for assistance in making the computational analysis of the binding mode of WA with KPNB1 and VCP and Yanjing Zhang and Yinchan Wang from Core Facilities of West China Hospital for assistance in the BLI assay. This work was supported by the National Natural Science Foundation of China (82473776 and 8257131365), the Sichuan Science and Technology Program (2024NSFSC1871, 2024YFHZ0185, and 2025YFHZ0313), the Foundation of Sichuan University (2018SCUH0067), and Science and Technology Achievement Transformation Fund of West China Hospital, Sichuan University (CGZH19010).
Author contributions
Z.L., A.S., H.Y., and W.W. designed research; Z.X., X.C., T.H., P.L., J.H., Y.Q., N.L., L.M., R.L., J.Z., and W.W. performed research; W.W. contributed new reagents/analytic tools; Z.X., X.C., T.H., P.L., and W.W. analyzed data; and Z.X., X.C., T.H., P.L., H.Y., and W.W. wrote the paper.
Competing interests
The authors declare no competing interest.
Footnotes
This article is a PNAS Direct Submission. C.C.W. is a guest editor invited by the Editorial Board.
Contributor Information
Zhihui Li, Email: Rockoliver163@163.com.
Anping Su, Email: suanpingping@126.com.
Haoyu Ye, Email: haoyu_ye@scu.edu.cn.
Wenshuang Wu, Email: wenshuang_wu@163.com.
Data, Materials, and Software Availability
Bulk RNA-seq data of ATC, PTC, and normal thyroid were retrieved from GEO (GSE29265; GSE33630; GSE65144; GSE76039) (50–53). mRNA expression counts and clinical information of PTC were downloaded from TCGA. All other data are included in the article and/or SI Appendix.
Supporting Information
References
- 1.Jackson S. P., Bartek J., The DNA-damage response in human biology and disease. Nature 461, 1071–1078 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Huang R., Zhou P. K., DNA damage repair: Historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct. Target Ther. 6, 254 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Taylor A. M. R., et al. , Chromosome instability syndromes. Nat. Rev. Dis. Primers 5, 64 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R. A., DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 8, 193–204 (2008). [DOI] [PubMed] [Google Scholar]
- 5.Groelly F. J., Fawkes M., Dagg R. A., Blackford A. N., Tarsounas M., Targeting DNA damage response pathways in cancer. Nat. Rev. Cancer 23, 78–94 (2023). [DOI] [PubMed] [Google Scholar]
- 6.Meyer H., Bug M., Bremer S., Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat. Cell Biol. 14, 117–123 (2012). [DOI] [PubMed] [Google Scholar]
- 7.Torrecilla I., Oehler J., Ramadan K., The role of ubiquitin-dependent segregase p97 (VCP or Cdc48) in chromatin dynamics after DNA double strand breaks. Philos. Trans. R. Soc. Lond. B Biol. Sci. 372, 20160282 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ji Z., et al. , Translocation of polyubiquitinated protein substrates by the hexameric Cdc48 ATPase. Mol. Cell 82, 570–584 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Acs K., et al. , The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks. Nat. Struct. Mol. Biol. 18, 1345–1350 (2011). [DOI] [PubMed] [Google Scholar]
- 10.Costantini S., Capone F., Polo A., Bagnara P., Budillon A., Valosin-containing protein (VCP)/p97: A prognostic biomarker and therapeutic target in cancer. Int. J. Mol. Sci. 22, 10177 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Mannar D., Ahmed S., Subramaniam S., AAA ATPase protein-protein interactions as therapeutic targets in cancer. Curr. Opin. Cell Biol. 86, 102291 (2023). [DOI] [PubMed] [Google Scholar]
- 12.Yang Y., et al. , Nuclear transport proteins: Structure, function, and disease relevance. Signal Transduct. Target Ther. 8, 425 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Kimura M., et al. , Extensive cargo identification reveals distinct biological roles of the 12 importin pathways. Elife 6, e21184 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Forbes D. J., Travesa A., Nord M. S., Bernis C., Nuclear transport factors: Global regulation of mitosis. Curr. Opin. Cell Biol. 35, 78–90 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Chi R. A., van der Watt P., Wei W., Birrer M. J., Leaner V. D., Inhibition of Kpnβ1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. BMC Cancer 21, 106 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Kimoto C., et al. , Functional characterization of importin α8 as a classical nuclear localization signal receptor. Biochim. Biophys. Acta 1853, 2676–2683 (2015). [DOI] [PubMed] [Google Scholar]
- 17.Yang J., et al. , Inhibition of Karyopherin beta 1 suppresses prostate cancer growth. Oncogene 38, 4700–4714 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Kodama M., et al. , In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 114, 7301–7310 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Zhu Z. C., Liu J. W., Li K., Zheng J., Xiong Z. Q., KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells. Oncogene 37, 2936–2952 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Atanasov A. G., Zotchev S. B., Dirsch V. M., Supuran C.T.; International Natural Product Sciences Taskforce, Natural products in drug discovery: Advances and opportunities. Nat. Rev. Drug Discov. 20, 200–216 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Molinaro E., et al. , Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 13, 644–660 (2017). [DOI] [PubMed] [Google Scholar]
- 22.Xing Z., et al. , Withaferin A: A dietary supplement with promising potential as an anti-tumor therapeutic for cancer treatment-pharmacology and mechanisms. Drug Des. Devel. Ther. 17, 2909–2929 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Cingolani G., Petosa C., Weis K., Müller C. W., Structure of importin-β bound to the IBB domain of importin-α. Nature 399, 221–229 (1999). [DOI] [PubMed] [Google Scholar]
- 24.Yang J., et al. , The natural compound Withaferin A covalently binds to Cys239 of β-tubulin to promote tubulin degradation. Mol. Pharmacol. 96, 711–719 (2019). [DOI] [PubMed] [Google Scholar]
- 25.Meerang M., et al. , The ubiquitin-selective segregase VCP/p97 orchestrates the response to DNA double-strand breaks. Nat. Cell Biol. 13, 1376–1382 (2011). [DOI] [PubMed] [Google Scholar]
- 26.Sancar A., Lindsey-Boltz L. A., Unsal-Kaçmaz K., Linn S., Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 39–85 (2004). [DOI] [PubMed] [Google Scholar]
- 27.Evan G. I., Vousden K. H., Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342–348 (2001). [DOI] [PubMed] [Google Scholar]
- 28.Syed Y. Y., Selinexor: First global approval. Drugs 79, 1485–1494 (2019). [DOI] [PubMed] [Google Scholar]
- 29.Nachmias B., Schimmer A. D., Targeting nuclear import and export in hematological malignancies. Leukemia 34, 2875–2886 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Shi A., et al. , KPNB1-mediated nuclear import in cancer. Eur. J. Pharmacol. 955, 175925 (2023). [DOI] [PubMed] [Google Scholar]
- 31.Han Y., Wang X., The emerging roles of KPNA2 in cancer. Life Sci. 241, 117140 (2020). [DOI] [PubMed] [Google Scholar]
- 32.Yang J., et al. , Inhibition of KPNA4 attenuates prostate cancer metastasis. Oncogene 36, 2868–2878 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Schmitt E. K., Hoepfner D., Krastel P., Natural products as probes in pharmaceutical research. J. Ind. Microbiol. Biotechnol. 43, 249–260 (2016). [DOI] [PubMed] [Google Scholar]
- 34.Ozorowski G., Ryan C. M., Whitelegge J. P., Luecke H., WithaferinA binds covalently to the N-terminal domain of annexin A2. Biol. Chem. 393, 1151–1163 (2012). [DOI] [PubMed] [Google Scholar]
- 35.Bargagna-Mohan P., et al. , Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosis. J. Biol. Chem. 285, 7657–7669 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Antony M. L., et al. , Growth arrest by the antitumor steroidal lactone withaferin A in human breast cancer cells is associated with down-regulation and covalent binding at cysteine 303 of β-tubulin. J. Biol. Chem. 289, 1852–1865 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Soderholm J. F., et al. , Importazole, a small molecule inhibitor of the transport receptor importin-β. ACS Chem. Biol. 6, 700–708 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.van der Watt P. J., et al. , Targeting the nuclear import receptor Kpnβ1 as an anticancer therapeutic. Mol. Cancer Ther. 15, 560–573 (2016). [DOI] [PubMed] [Google Scholar]
- 39.Christie M., et al. , Structural biology and regulation of protein import into the nucleus. J. Mol. Biol. 428, 2060–2090 (2016). [DOI] [PubMed] [Google Scholar]
- 40.Görlich D., Vogel F., Mills A. D., Hartmann E., Laskey R. A., Distinct functions for the two importin subunits in nuclear protein import. Nature 377, 246–248 (1995). [DOI] [PubMed] [Google Scholar]
- 41.Cingolani G., Bednenko J., Gillespie M. T., Gerace L., Molecular basis for the recognition of a nonclassical nuclear localization signal by importin β. Mol. Cell 10, 1345–1353 (2002). [DOI] [PubMed] [Google Scholar]
- 42.van den Boom J., Meyer H., VCP/p97-mediated unfolding as a principle in protein homeostasis and signaling. Mol. Cell 69, 182–194 (2018). [DOI] [PubMed] [Google Scholar]
- 43.Magnaghi P., et al. , Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat. Chem. Biol. 9, 548–556 (2013). [DOI] [PubMed] [Google Scholar]
- 44.Roux B., et al. , Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Sci. Transl. Med. 13, eabg1168 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Saha I., et al. , The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system. Nat. Commun. 14, 560 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Wang F., et al. , Allosteric p97 inhibitors can overcome resistance to ATP-competitive p97 inhibitors for potential anticancer therapy. ChemMedChem 15, 685–694 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Tao S., et al. , Withaferin A analogs that target the AAA+ chaperone p97. ACS Chem. Biol. 10, 1916–1924 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Körner M., et al. , The FAM104 proteins VCF1/2 promote the nuclear localization of p97/VCP. Elife 12, e92409 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Wrobel L., Hoffmann J. L., Li X., Rubinsztein D. C., p37 regulates VCP/p97 shuttling and functions in the nucleus and cytosol. Sci. Adv. 10, eadl6082 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Tomas G., Vincent D., Sporadic vs. post-chernobyl papillary vs. anaplastic thyroid cancers. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29265. Accessed 21 October 2023.
- 51.Tomas G., Vincent D., Normal thyrocytes vs papillary vs anaplastic thyroid carcinomas. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33630. Accessed 21 October 2023.
- 52.Roemeling C. A. von, Copland J. A., Tun H. W., Gene array analysis of anaplastic thyroid carcinoma tissue versus matched and unmatched normal thyroid tissue. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65144. Accessed 21 October 2023.
- 53.Landa I., et al. , Genomic and transcriptomic hallmarks of poorly-differentiated and anaplastic thyroid cancers. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76039. Accessed 21 October 2023. [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Appendix 01 (PDF)
Data Availability Statement
Bulk RNA-seq data of ATC, PTC, and normal thyroid were retrieved from GEO (GSE29265; GSE33630; GSE65144; GSE76039) (50–53). mRNA expression counts and clinical information of PTC were downloaded from TCGA. All other data are included in the article and/or SI Appendix.








